13,332 Shares in Vericel Co. (NASDAQ:VCEL) Acquired by Intech Investment Management LLC

Intech Investment Management LLC purchased a new position in Vericel Co. (NASDAQ:VCEL - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 13,332 shares of the biotechnology company's stock, valued at approximately $563,000.

Several other institutional investors have also recently added to or reduced their stakes in VCEL. Geneva Capital Management LLC grew its position in shares of Vericel by 61.4% in the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company's stock worth $46,660,000 after acquiring an additional 420,078 shares in the last quarter. Congress Asset Management Co. increased its stake in Vericel by 37.4% during the third quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company's stock valued at $54,575,000 after purchasing an additional 351,550 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of Vericel by 34.9% in the 2nd quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company's stock worth $38,575,000 after buying an additional 217,437 shares during the last quarter. TimesSquare Capital Management LLC boosted its holdings in shares of Vericel by 54.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company's stock valued at $24,934,000 after buying an additional 209,009 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in shares of Vericel by 51.5% in the 2nd quarter. Victory Capital Management Inc. now owns 611,146 shares of the biotechnology company's stock valued at $28,039,000 after buying an additional 207,714 shares during the period.

Insider Buying and Selling

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total value of $150,000.00. Following the completion of the transaction, the director now owns 26,595 shares of the company's stock, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the sale, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. This trade represents a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,666 shares of company stock worth $1,350,764. Corporate insiders own 5.20% of the company's stock.

Vericel Stock Performance

Shares of NASDAQ:VCEL traded up $0.60 during trading on Monday, reaching $58.74. The company had a trading volume of 376,884 shares, compared to its average volume of 430,558. The firm's fifty day moving average is $47.60 and its 200 day moving average is $47.41. The firm has a market capitalization of $2.90 billion, a PE ratio of 979.16 and a beta of 1.66. Vericel Co. has a twelve month low of $32.31 and a twelve month high of $61.49.

Vericel (NASDAQ:VCEL - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Equities analysts predict that Vericel Co. will post 0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a report on Friday, November 8th. TD Cowen raised their target price on Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 27th. Canaccord Genuity Group initiated coverage on shares of Vericel in a report on Friday, August 9th. They set a "buy" rating and a $57.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Vericel in a report on Friday, November 8th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $60.00 target price on shares of Vericel in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Vericel has a consensus rating of "Moderate Buy" and a consensus target price of $59.71.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.